{
    "Trade/Device Name(s)": [
        "ADVIA Centaur HAV Total Assay",
        "ADVIA Centaur HAVT Assay",
        "ADVIA Centaur Hepatitis A Total (HAVT) Assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K142758",
    "Predicate Device Reference 510(k) Number(s)": [
        "K060678"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LOL"
    ],
    "Summary Letter Date": "September 23, 2014",
    "Summary Letter Received Date": "September 25, 2014",
    "Submission Date": "December 5, 2014",
    "Regulation Number(s)": [
        "21 CFR 866.3310"
    ],
    "Regulation Name(s)": [
        "Hepatitis A virus (HAV) serological assays"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "serology"
    ],
    "Analyte(s)": [
        "Total antibodies to hepatitis A virus (anti-HAV)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Potassium EDTA tube",
        "Lithium heparin tube",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur system",
        "ADVIA Centaur XP system",
        "ADVIA Centaur CP system"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoassay",
        "Competitive immunoassay",
        "Chemiluminescence"
    ],
    "Methodologies": [
        "Immunoassay",
        "Competitive immunoassay",
        "Chemiluminescent detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Kit",
        "Calibrator",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur HAV Total Assay, a competitive immunoassay for qualitative detection of anti-HAV antibodies in serum and plasma using chemiluminescence technology",
    "Indications for Use Summary": "In vitro qualitative immunoassay for total antibodies to hepatitis A virus (anti-HAV) in neonatal, pediatric, and adult serum or plasma, as an aid in diagnosis of hepatitis A infection or identification of HAV-susceptible individuals for vaccination; not cleared or approved for blood/plasma donor screening",
    "fda_folder": "Microbiology"
}